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Steroid hormones complexed with their receptors play an essential role in the regulation of mouse mammary
tumor virus (MMTV) transcription. However, the need for additional tissue-specific regulatory factors is
suggested by the lack of virus expression in liver, in which glucocorticoid receptors are highly abundant, and
by the tissue-specific transcription of reporter genes linked to an MMTV long terminal repeat in transgenic
mice. In this study, we characterized two distal-region regulatory elements, DRa and DRc, which, together with
the distal glucocorticoid receptor binding site (DRb), increased transcription from the MMTV promoter in
permissive cells. This was demonstrated by transfection of these sequences (DRa, DRb, and DRc) in different
combinations with the natural MMTV promoter in mouse fibroblasts and mammary epithelial cells, followed
by quantitative S1 nuclease mapping of the transcripts. We further showed by DNase I footprinting, methyl-
ation interference, and gel retardation assays with various nuclear extracts from permissive or nonpermissive
tissues and cell lines that the factors binding to the DRa site are distinct and tissue-specific whereas those
binding to DRc are ubiquitous.
Mouse mammary tumor virus (MMTV) is a slow-transform-
ing retrovirus that induces carcinomas of the mammary gland
in susceptible mouse strains. The virus can be transmitted
either exogenously as viral particles through the milk or endo-
genously through the germ line as integrated proviruses (re-
viewed in reference 26). Studies involving the generation of
transgenic mice carrying DNA constructs in which the MMTV
long terminal repeat (LTR) is linked to a reporter gene (65, 72,
77) or drives the expression of a transforming gene (44, 54)
showed that the mammary gland is a major site of expression.
However, other tissues such as lymphoid organs, salivary
glands, seminal vesicles, prostate, and testes were often found
to express the transgene at lower levels.
The infection of mammary epithelial cells leads to the in-
sertion of DNA in the host cell genome. Provirus expression
involves protein factors binding to specific DNA sequences in
the LTR. Steroid hormones such as glucocorticoids (8), pro-
gestins (12, 22), and androgens (16, 28) bound to their recep-
tors were shown to positively regulate MMTV gene expression
in cells derived from mammary tumors, in infected cell lines
(62, 83), and in cells transfected with cloned MMTV DNA (8,
13, 32, 39). This class of positively acting factors induces the
expression of MMTV through DNA sequences within the U3
region of the LTR. The hormone-responsive element (HRE)
extends to approximately 200 bp upstream of the transcription
start site (9, 33, 43). A distal element (around position 2175)
and a proximal one (around 2120), shown to bind the purified
glucocorticoid receptor in vitro (59, 69), act cooperatively and
with other sites of the HRE to achieve maximum glucocorti-
coid stimulation of the MMTV promoter (Fig. 1) (3, 6, 10, 11,
13, 37, 48). It has been shown that mutations of a binding site
for nuclear factor I (around position270) impair the glucocor-
ticoid-stimulated transcription from the MMTV promoter,
providing evidence for the involvement of a nonreceptor pro-
tein in the hormonal response (10, 11, 13, 48, 76).
In several studies with transgenic mice carrying the MMTV
LTR linked to a reporter gene, the pattern of organs express-
ing the transgene did not correlate with the abundance of
glucocorticoid receptor in their cells. The expression of the
transgene was never detected in the liver (63, 65, 72), despite
its high level of glucocorticoid receptor (25, 53). Thus, the
presence of this receptor does not seem to be sufficient to allow
transcription from the MMTV LTR. The tissue tropism of
MMTV may be mediated by the combined action of hormone
receptors and of modulatory factors bound to cis-acting ele-
ments. By functional assays in tissue culture cells, several pos-
itive and negative regulatory elements have been identified in
the 59 part of the LTR (21, 29, 41, 49, 50, 52, 81). Moreover,
the involvement of regions located outside of the HRE in the
tissue-specific expression of MMTV was defined by the gener-
ation of transgenic mice (reviewed in reference 26) and by the
analysis of cloned MMTV variant proviruses, isolated from
T-cell lymphomas, with alterations in the U3 region of their
LTRs (40, 47). These variants of MMTV display internal de-
letions of about 400 to 500 bp which are thought to be related
to the tissue-specific expression of MMTV in T lymphocytes
(31, 74, 80). The overexpression of MMTV genes in T lym-
phocytes and the extended range of expressing organs (also
including brain, heart, and skeletal muscle) observed with a
reporter transgene under the control of a partially deleted
MMTV LTR (65) could be explained by the deletion of neg-
ative regulatory elements or by the loss of some tissue-specific
elements involved in mammary gland expression.
A possible way of achieving glucocorticoid-dependent tran-
scription may be by interactions between the receptor and
additional regulatory factors, as suggested by the results of a
previous study from our laboratory (46) that investigated the
binding of nuclear proteins to MMTV DNA in the vicinity of
the distal glucocorticoid receptor-binding site, the main DNA
element required for the glucocorticoid stimulation of MMTV
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transcription. By DNase I in vitro footprinting assays using
nuclear extracts from mouse liver or salivary glands, an ex-
tended protected area was identified in the promoter distal
region (DR) around position 2200 upstream of the transcrip-
tion start site (Fig. 1). It was demonstrated that its 39 part
(DRb, 2170 to 2186) interacts with the glucocorticoid recep-
tor, whereas the protected sequence extending to the 59 side
(DRa, 2189 to 2206) showed different hypersensitive sites.
Moreover, nuclear extracts from two different tissues (liver and
salivary glands) contained proteins that bound to the DRa
sequence with a distinct mobility in a gel retardation assay (46).
As liver and salivary glands also differ in their permissivity
for MMTV expression in transgenic animals, we decided to
pursue and extend the investigation. Using nuclear extracts
from various tissues, we confirmed in this study the correlation
between permissivity and formation of specific complexes with
DRa. We further demonstrated the tissue specificity of the
DRa-binding factors by methylation interference and compe-
tition with mutated oligonucleotides. In DNase I footprinting
experiments, we identified an additional binding activity to a
sequence (DRc, 2209 to 2218), located 59 of the DRa region.
This activity was found ubiquitously, but its abundance varied
in different tissues. We also describe transient transfection
experiments designed to determine the functional role of these
sequences in the regulation of MMTV transcription in re-
sponse to glucocorticoid hormones.
MATERIALS AND METHODS
Cell extracts. (i) For footprinting experiments.Nuclear extracts from livers (10
g), kidneys (4 g), and spleens (3 g) of 10 3-month-old BALB/c mice were
prepared by the method of Gorski et al. (20), with one modification. Minced
tissues were homogenized, cells were broken in the appropriate buffer, and
nuclei were pelleted only once through a sucrose cushion and then lysed. Nuclear
proteins were resuspended at a final concentration of 5 to 10 mg/ml.
(ii) For gel mobility shift assays. Nuclei from livers (10 g), kidneys (4 g),
spleens (3 g), and salivary glands (2 g) from 10 BALB/c mice were prepared as
previously described by Hagenbu¨chle and Wellauer (27), with some modifica-
tions. Minced tissues were homogenized in 0.3 M sucrose in buffer A (0.5
mM EGTA, 2 mM EDTA, 60 mM KCl, 15 mM NaCl, 0.15 mM spermine,
0.5 mM spermidine, 15 mM N-2-hydroxyethylpiperazine-N9-ethanesulfonic acid
[HEPES; pH 7.5], 14 mM 2-mercaptoethanol). The homogenate was filtered and
layered on top of a 10-ml cushion of 30% (wt/vol) sucrose in buffer A prior to
centrifugation for 10 min at 1,000 3 g (HB-4 swing-out rotor) and 48C. The
nuclear pellet was resuspended in 3 ml of 2 M sucrose in buffer A containing only
0.1 mM EGTA and 0.1 mM EDTA, layered on top of a 2-ml cushion of the same
solution, and recentrifuged in a Beckman SW50.1 rotor at 100,000 3 g for 1 h at
48C. The nuclei contained in the pellet were resuspended in buffer B (20 mM
Tris-HCl [pH 7.9], 75 mMNaCl, 0.5 mM EDTA, 0.85 mM dithiothreitol, 0.5 mM
phenylmethylsulfonyl fluoride, 25% [vol/vol] glycerol), counted, recentrifuged,
and resuspended in this buffer at a concentration of approximately 105 nuclei per
ml. Nuclear extracts from mouse mammary glands were prepared as described by
De Groot and Sassone-Corsi (17).
Whole-cell extracts from mouse cell lines (fibroblast L cells [Ltk2], normal
mammary epithelial cells [EF43], mammary tumor cells [GR], B-cell hybridoma
[LBB], and T-cell lymphoma [RG17]) were prepared by the method of Paterson
and Everett (57). All extracts were made in the presence of the protease inhibitor
phenylmethylsulfonyl fluoride (0.5 mM).
DNase I footprinting. DNase I footprinting assays were performed according
to published modifications (46) of the original method (18). An asymmetrically
radiolabeled DNA probe was prepared by incubation of plasmid pGLTR (pro-
vided by B. Ku¨hnel) with HindIII (cleaving at position 148, where a synthetic
HindIII linker was inserted) followed by 59 end labeling with [g-32P]ATP and
digestion with StyI (position 2303). The purified labeled fragment (5 fmol) was
incubated on ice for 30 min with 1 mg of double-stranded poly(dI-dC) competitor
DNA and 60 mg of liver, kidney, or spleen nuclear extracts in a 20-ml binding
reaction mixture as previously described (46). In competition experiments, the
indicated amount of double-stranded oligonucleotides in 1 ml was added to the
binding reaction mixture 10 min prior to the addition of the labeled DNA.
DNase I (Pharmacia) at 5,000 U/ml was freshly diluted as necessary (to
approximately 250 U/ml), and 1 ml was added to the binding reaction mixture.
Digestion was allowed to proceed for 3 to 5 min on ice and was stopped by adding
180 ml of a solution containing sodium dodecyl sulfate and proteinase K (46).
Reextracted DNA samples were loaded onto a 6% denaturing polyacrylamide
gel.
Gel mobility shift assays. Oligonucleotides DRa, DRaMut(L) (DRaML),
DRaMut(S) (DRaMS), DRc, and DRcM (Fig. 1) were labeled at the 59 end with
[g-32P]ATP and T4 polynucleotide kinase before annealing with the complemen-
tary strand. A portion (20 fmol) was incubated on ice for 30 min in a 20-ml
binding reaction mixture containing 4 ml of buffer (175 mM NaCl, 55 mM
HEPES [pH 7.6], 40 mM MgCl2, 0.5 mM EDTA, 55% glycerol), 1 mM dithio-
threitol, 1 mg of double-stranded poly(dI-dC) competitor DNA, and 20 mg of
whole-cell nuclear protein from cultured cell lines. In the case of extracts from
mouse tissues, 5 3 105 nuclei of spleen or 106 nuclei of liver or kidney were used
with the DRa, DRaML, and DRaMS oligonucleotides, and conversely for the
DRc and DRcM oligonucleotides. With the mammary gland nuclear extract, 5 to
10 mg was used in the different reactions. The salt concentration in the protein-
FIG. 1. Schematic representation of the 39 end of the regulatory region of the MMTV LTR. The TATA box, the basal promoter region (BPR), the proximal region
(PR), and the DR are indicated by hatched boxes. DNase I protection assays have defined the distal binding sites for the glucocorticoid receptor (DRb) and for factors
binding its 59 flanking region (DRa). The newly observed protein-binding site (DRc), extending the distal region to position 2218, is located next to DRa. The
double-stranded oligonucleotides used in this study are indicated by the brackets above the sequences of DRa, DRb, and DRc in the coding strand. The sequences of
the mutated oligonucleotides (coding strand) DRaMut (L), DRaMut (S), and DRcM are shown in the boxes below; white residues in black squares denote the mutated
bases.
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DNA binding reaction mixture was adjusted to 60 mM as in the whole-cell
extract. Samples were analyzed on a 5% nondenaturing polyacrylamide gel.
Methylation interference experiments. Double-stranded oligonucleotides
DRa and DRc, 32P-labeled at the 59 end of the coding strand as for gel mobility
shift assays, were methylated in 200 ml of 50 mM sodium cacodylate–1 mM
EDTA (pH 8.0) by addition of 1 to 4 ml of 98.9% dimethyl sulfate and incubation
for 5 min at room temperature. The reaction was stopped by adding 40 ml of 1.5
M sodium acetate (pH 7.0)–1.0 M 2-mercaptoethanol. After two precipitations
with ethanol, the DNA was incubated with nuclei from mouse tissues (liver and
spleen) to perform a gel mobility shift assay. Double-stranded oligonucleotides
bound to proteins as well as unbound ones were electroeluted from the respec-
tive gel slices and ethanol precipitated. G..A..T or G cleavages of the eluted
methylated duplexes were performed with NaOH or piperidine. These proce-
dures as well as electrophoresis in 20% acrylamide–7 M urea gels were carried
out according to published protocols (45).
Plasmid constructions. Construction of plasmids pLS wild type and pLS2172/
2162 was described previously (10, 37). They consist of the MMTV (GR strain)
LTR (either wild type or with an 8-bp HindIII linker replacing the DNA between
positions 2172 and 2162) in front of the coding portion of the herpesvirus
thymidine kinase gene in a pBR322 vector. Plasmids pLS DRb, pLS DRb1a, and
pLS DRb1a1c were newly constructed and used for the generation of pLS
DRb1c and pLS DRb1a1c1c. Plasmid pLS 2172/2162 was digested with
HindIII and EcoRI. The DNA fragment containing the 59 end of the LTR was
removed and replaced by double-stranded oligonucleotides with the sequence of
DRb alone, DRb1a, or DRb1a1c and aHindIII cohesive end (Fig. 1). Plasmids
pLS DRb1c and pLS DRb1a1c1c were obtained by blunt-end ligation of the
double-stranded DRc oligonucleotide in front of either the DRb (in pLS DRb)
or the DRc (in pLS DRb1a1c) sequence. The presence and orientation of the
different inserts were verified by sequencing.
Cell culture and transfection. Mouse Ltk2 cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum and antibi-
otics. Mouse mammary epithelial EF43 cells were grown in this medium with
addition of insulin (5 mg/ml) and epidermal growth factor (10 ng/ml). Cells were
grown in 100-mm-diameter culture dishes until they reached approximately 60 to
70% confluency. Transient transfections were carried out by the DEAE-dextran
method with 15 mg of MMTV plasmid and 1 mg of plasmid H514, containing the
rabbit b-globin gene and simian virus 40 enhancer sequences (4). The cultures
were incubated with DNA for 6 h, subjected to a 10% dimethyl sulfoxide shock
for 1.5 min at room temperature, washed, and incubated with complete medium
for a further 42 h. Dexamethasone (Sigma) was added to a final concentration of
5 3 1027 M, 17 h before RNA extraction.
RNA extraction and S1 mapping. Total cellular RNA was extracted from
transiently transfected cells by the guanidinium thiocyanate method, digested
with RNase-free DNase I, extracted with phenol-chloroform, and reprecipitated
with ethanol. For the S1 nuclease mapping experiments, the following DNA
fragments were labeled at the 59 end with [g-32P]ATP: for the analysis of MMTV
transcripts, the EcoRI-BamHI fragment of plasmid pD47B (37) extending from
2204 to 1142; for the b-globin internal standard, the 2.5-kb BamHI fragment of
pH514 (37). RNA (25 or 50 mg) was hybridized to 5 or 10 fmol of 59 end-labeled
MMTV or b-globin probe in 20 ml at 528C for 16 h and digested with 1,000 U of
S1 nuclease per ml for 45 min at room temperature. Protected fragments were
separated by electrophoresis in denaturing 6% polyacrylamide gels and subjected
to autoradiography. The intensity of the bands was quantified by densitometric
scanning of the films.
RESULTS
Tissue-specific and ubiquitous proteins binding to the distal
region of the MMTV promoter. For the analysis of proteins
binding in the vicinity of the distal glucocorticoid regulatory
element (DRb site; from 2170 to 2186), we prepared nuclear
extracts from three different mouse organs: spleen (permis-
sive for MMTV expression) and liver and kidney (both non-
permissive tissues). DNase I footprinting experiments were
performed with a radiolabeled DNA fragment spanning the pro-
moter region of MMTV (from2303 to148) and unfractionated
nuclear extracts from these tissues. Two predominant areas of the
coding strand were protected from DNase I cleavage (Fig. 2A),
one in the DR and the other in the basal promoter region.
In the DR, the 39 part of the footprint (DRb) was very
similar with all tissue extracts and is due to the glucocorticoid
receptor, as shown previously (46). The protection extending
to the 59 side (DRa, 2189 to 2206) showed tissue-specific
differences, indicating the presence of a binding activity that is
distinct from the glucocorticoid receptor. With liver (Fig. 2A,
lane 2) and kidney (data not shown) nuclear extracts, two
strong hypersensitive sites were observed at the 59 boundary of
DRa at positions 2207 and 2208, in agreement with results
obtained previously in our laboratory, whereas with the spleen
extract (Fig. 2A, lane 3), the protected area extended to posi-
tion 2218 without interruptions. The additional protein-bind-
ing site, located upstream from DRa, was designated DRc
(2207 to 2218). Interestingly, closer examination of the foot-
prints obtained with salivary glands and L-cell nuclear extracts
by Meulia and Diggelmann (46) revealed a similar extended
protected area with no hypersensitive sites at the 59 boundary
of DRa. Thus, the presence of hypersensitive sites between
DRa and DRc seems to be a particular feature of nonpermis-
sive tissues. A DRc-binding activity also exists in nonpermis-
sive tissues, as shown by the smaller protected area from 2211
to 2218 seen with liver nuclear extract (Fig. 2A, lane 2).
To investigate whether one or more binding activities were
involved in the protection of DRa and DRc, we performed
oligonucleotide competition experiments. In spleen nuclear
extract, a 500-fold molar excess of a double-stranded DRc
oligonucleotide (Fig. 1) abolished the protection of DRc but
not of DRa (Fig. 2B, lane 9), indicating that two distinct bind-
ing activities contribute to the extended footprint up to posi-
tion 2218. In liver nuclear extract, competition with the DRc
oligonucleotide caused the disappearance of the footprint be-
tween 2211 and 2218 (Fig. 2C, lane 3). With both types of
extracts, we observed that competition with the DRc oligonu-
cleotide also impaired the protection of DRb, suggesting that
the binding of the glucocorticoid receptor is affected. Control
experiments with a 500-fold molar excess of the nonspecific
competitor VW, containing the sequence of the promoter re-
gion of adenovirus type 2 (67), did not alter the DNase I
protection pattern seen in the absence of competitor (Fig. 2B,
lane 8; Fig. 2C, lane 4).
Double-stranded oligonucleotides with either the DRa or
the DRb sequence (Fig. 1) competed for the footprint in the
homologous region (Fig. 2B), showing that two distinct binding
activities of spleen (permissive) nuclear extracts were respon-
sible for the footprint from 2170 to 2207 (Fig. 2B, lane 6 and
7). A binding activity distinct from the glucocorticoid receptor
was also seen with liver (nonpermissive) nuclear extracts (Fig.
2B, lane 3 and 4) as previously observed (46). At a 500-fold
molar excess, the DRb oligonucleotide also affected the footprint
in DRc (Fig. 2B, lane 3). Likewise, competition with the DRa
oligonucleotide altered the footprint in DRb (Fig. 2B, lane 7).
Tissue-specific features were also observed in the basal pro-
moter region. As expected, extracts from all tested tissues
protected an area covering the nuclear factor I and III (Oct-1)
recognition sites (7, 46, 56). However, with the nonpermissive
tissue extracts (liver and kidney), the protected area extended
to DNA sequences closer to the TATA box, while with the
permissive tissue extracts (spleen), the protection extended
further upstream, in the direction of the proximal region (Fig.
2). The pattern observed with the spleen extract may be rep-
resentative of permissive tissues in general, as it was also dis-
played by nuclear extracts of salivary glands (46).
As the results of the footprinting experiments showed that
the major differences between extracts from permissive and
nonpermissive tissues concerned the 59 part (DRa and DRc) of
the DR, we performed gel retardation assays using oligonucle-
otides with the DRa or the DRc sequence (Fig. 3). Extracts
from murine permissive cell lines (Ltk2 fibroblasts, EF43 nor-
mal mammary epithelial cells, GR mammary tumor cells, and
the lymphoid cell lines RG17 and LBB) and from lactating
mammary glands were used, in addition to the tissue extracts
mentioned previously for the footprinting experiments. When
the labeled DRa oligonucleotide was incubated with the dif-
ferent nuclear extracts, two distinct major DNA-protein com-
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plexes were observed (Fig. 3A, large arrows). All of the ex-
tracts from permissive tissues or cells formed complexes with
similar mobilities (Fig. 3A, lanes 2 to 8), migrating faster than
those formed by the nonpermissive extracts (Fig. 3A, lane 1;
see also Fig. 6B, lane 2). We noticed that in gel retardation
assays performed in 2% agarose rather than 5% polyacryl-
amide, the mobility of the complexes formed with permissive
tissue extracts (e.g., spleen and L cells) was slightly lower than
that of complexes formed with nonpermissive extracts, in
agreement with previous observations (salivary glands [46])
(data not shown). It is likely that the permissive tissue com-
plexes described in this and the previous study (46) are highly
related, especially since the patterns of DNase I protection
were identical for spleen, salivary glands, and L cells (showing
no hypersensitive sites at positions 2207 and 2208 in contrast
to nonpermissive tissues). The lower band in Fig. 3A, lane 1
(marked by a small arrow) was present in variable amounts in
different experiments and is most likely due to proteolytic
cleavage (compare Fig. 3A, lane 1, with Fig. 6A, lane 1). In
quantitative terms, lower amounts of DRa-bound complexes
were observed with permissive extracts than with nonpermis-
sive extracts, suggesting a low level of expression or a weak
affinity for the DRa sequence.
In contrast, when the DRc oligonucleotide was incubated
FIG. 2. DNase I footprinting analysis with crude liver and spleen nuclear extracts. A DNA fragment comprising the sequences from the StyI restriction site at
positions 2303 to 148, where a synthetic HindIII linker was inserted, was 59 labeled at the StyI site. The 352-bp fragment was incubated with 25 mg of bovine serum
albumin (lane 1) or with 50 mg of nuclear proteins from liver (A, lane 2; B, lanes 2 to 4; C, lanes 2 to 4) or spleen (A, lane 3; B, lanes 5 to 9). The complexes were
then subjected to DNase I digestion. The two major protected areas in the basal promoter region (BPR) and in the DR are indicated by brackets. In competition
experiments (B and C), oligonucleotide DRb, DRa, or DRc (see Fig. 1) was preincubated with the extracts in 500-fold molar excess over the labeled probe. The
nonspecific competitor VW from the adenovirus promoter was also added at 500-fold molar excess (B, lane 8; C, lane 4).
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with nuclear extracts from both permissive (Fig. 3B, lanes 3 to
6 and 8) and nonpermissive tissues or cells (lanes 1, 2, and 7),
the specific protein-DNA complex exhibited the same gel mo-
bility. However, the intensity of the signal was stronger when
extracts from permissive tissues were used. This result indi-
cates a quantitative rather than a qualitative difference be-
tween the two types of extracts, suggesting that the abundance
of DRc-binding factor(s) is higher in permissive organs. The
upper band seen in some experiments is due to nonspecific
binding and is not reproducible (see Fig. 7).
Methylation interference analysis of the DNA-protein con-
tact points in DRa and DRc. By gel retardation assay, we
observed the formation of complexes with different mobilities
(in DRa) or with the same mobility (in DRc). To further
characterize the complexes, we decided to perform methyl-
ation interference assays, which allow the determination of the
protein-DNA contact points, on these DNA sequences (Fig.
4). The double-stranded oligonucleotides DRa and DRc, la-
beled on one strand and partially methylated, were used as
substrates in a reaction with dimethyl sulfate and thereafter as
probes in a gel retardation assay. The bound (Fig. 4, lanes B)
and free (lanes F) forms of DNA were recovered from the
native gel, cleaved with piperidine or NaOH, and analyzed on
denaturing polyacrylamide gels. If methylation at a particular
residue interferes with protein binding, the corresponding
band in the autoradiograph is underrepresented in the popu-
lation of protein-bound fragments (lanes B).
When the DRa oligonucleotide was incubated with liver
nuclear extract (Fig. 4A), we observed the disappearance of
certain bands in lane 4 (bound) compared with lane 3 (free),
indicating the specific G bases which interact with protein. This
pattern of contact points was different from the pattern ob-
tained with proteins from a permissive nuclear extract (spleen;
lane 2), for which no reduction of the signals was observed. To
determine contact points on DRa with proteins from spleen
nuclear extract, the methylated DNA was cleaved with NaOH
instead of piperidine, thus allowing the analysis of a broader
spectrum of bases (G..A [..T if high concentrations of
dimethyl sulfate are used]; Fig. 4B). Only a partial interference
was observed, which could be explained by the low amount of
complexes found in the gel retardation assays. The results
obtained for liver with NaOH treatment (Fig. 4C) confirmed
and extended those of Fig. 4A. On the other hand, the contact
points on DRc with nuclear extracts from liver, spleen, or L
cells were all the same (Fig. 4D). In conclusion, proteins from
the various extracts which formed similarly migrating com-
plexes with DRc also had identical contact points with the
DNA (Fig. 5). Conversely, in DRa, proteins from permissive
and nonpermissive tissues showed different sets of contact
points with the DNA (Fig. 5), further supporting the evidence
from the footprinting and gel retardation assays for two dis-
tinct DRa-binding activities.
Specificity of the DNA-protein interactions. To prove that
the protein-DNA complexes observed with DRa were tissue
specific, gel retardation assays were performed with double-
stranded oligonucleotides (Fig. 1) mutated in the specific res-
idues shown by methylation interference to be important for
the binding of proteins from the different extracts. Compared
with wild-type DRa (Fig. 6A, lane 1; Fig. 6B, lanes 1 and 2),
oligonucleotide DRaML, carrying three mutations in the liver-
specific contact points, no longer formed the specific complex
with extracts from liver (Fig. 6A, lane 2) or from kidney,
another nonpermissive tissue (Fig. 6B, lane 3). In contrast,
oligonucleotide DRaML was not impaired in the formation of
the permissive-tissue complex (Fig. 6A, lane 7); it was rather
more efficient than wild-type DRa, possibly by fortuitously
creating a better binding site (Fig. 6A; compare lanes 6 and 7).
This fact may account for the low level of permissive-type
complex seen with the nonpermissive kidney extract and oli-
gonucleotide DRaML (Fig. 6B, lane 3), a complex which is
normally barely detectable with the wild-type DRa oligonucle-
otide (Fig. 3A, lane 1; Fig. 6A, lane 1; Fig. 6B, lane 2) but
which does appear occasionally in liver extracts (Fig. 6B, lane
1).
The specificity of the protein-DNA complexes formed with
the DRa site was determined by competition with homologous
or heterologous oligonucleotides. A 250-fold molar excess of
the unlabeled DRa oligonucleotide abolished the binding of
proteins from either permissive or nonpermissive extracts to
the labeled DRa probe (Fig. 6A, lanes 3 and 8), whereas an
unrelated oligonucleotide (VW) did not show any competition
(Fig. 6A, lanes 5 and 10). The mutated oligonucleotide
DRaML at a 250-fold molar excess did not compete for the
major DRa-binding activity from liver or kidney tissues (Fig.
6A, lane 4; Fig. 6B, lane 5), whereas it abolished the binding of
proteins from spleen to the DRa sequence (Fig. 6A, lane 9).
FIG. 3. Gel retardation assays using extracts from different sources and 59-
end-labeled oligonucleotide DRa (A) or DRc (B). (A) Oligonucleotide DRa was
incubated with extracts from nonpermissive tissue (liver [L; lane 1]) or from
permissive tissues (spleen [S; lane 2] and mammary gland [Mgd; lane 6] or other
cell types (fibroblasts [L cells {Lc}], B-cell hybridoma [LBB], T-cell lymphoma
[RG17], mammary epithelial cells [EF43], and mammary tumor cells [GR]; lanes
3 to 8). The upper arrow on the left indicates the specific DNA-protein complex
for nonpermissive tissues, and the arrow on the right indicates the specific
complex for permissive tissues or cells. (B) The labeled oligonucleotide DRc was
incubated with liver (L; lanes 2 and 7), kidney (K; lane 1), or spleen (S; lane 8)
nuclei or with nuclear extracts from the other cell types (lanes 3 to 6). The arrows
on the left indicate the specific DNA-protein complex.
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These results demonstrate that the major DRa-binding species
are different in permissive and nonpermissive tissues.
To determine if the proteins from permissive tissues of dif-
ferent origin had a common specificity to the DRa sequence,
we used an oligonucleotide (DRaMS; Fig. 1) mutated in five
contacted bases that are important for binding with spleen and
LBB nuclear extracts. Compared with the DRa probe (Fig. 6C,
odd-numbered lanes), the DRaMS sequence (Fig. 6C, even-
numbered lanes) bound only very weakly to protein extracts
from spleen and all other permissive tissues or cell lines tested,
suggesting that the DRa-binding activities in these tissues are
the same.
Similar experiments were carried out with an oligonucleo-
tide mutated in two contacted bases of DRc (DRcM; Fig. 1).
DRcM was unable to form specific complexes with either type
of nuclear protein extracts tested (Fig. 7, lanes 2 and 7), nor did
it compete for complex formation with the wild-type DRc
sequence (lanes 4 and 9). While Fig. 7 shows the data for two
prototype tissues (liver and spleen), several organs and cell
types were also studied (kidney, salivary glands, mammary
glands, and cell lines Ltk2, GR, EF43, LBB, and RG17; data
not shown); they all formed similar retarded complexes with
the DRc oligonucleotide (Fig. 2B) and were unable to bind
DRcM. Thus, contrary to DRa, no tissue specificity was ob-
served with the DRc sequence, demonstrating the ubiquity of
the factors involved.
Influence of the DRa and DRc sequences on MMTV pro-
moter activity. The tissue specificity of the factor(s) binding
DRa established the basis for an investigation of the functional
role of this region in a permissive situation. We used transient
transfection experiments in fibroblastic (Ltk2) and mammary
epithelial (EF43) cells to determine if the presence of the
sequences DRa and/or DRc could modify the level of tran-
scription from the MMTV promoter and influence the hor-
mone response. At first, three types of plasmids with the
MMTV promoter linked to the coding region of the herpes
simplex virus thymidine kinase gene were used. They contained
the 39 part of the MMTV LTR from positions 1134 to 2162,
to which synthetic double-stranded oligonucleotide DRb,
DRa1b, or DRc1a1b was added via a HindIII linker which
was shown previously not to interfere with the hormone re-
sponse (10). A plasmid with the complete LTR (pLS wild type)
served as a control in these experiments. The different con-
structions were transiently introduced into Ltk2 cells, known
to transcribe the MMTV promoter very efficiently after treat-
ment with dexamethasone (a synthetic glucocorticoid), or into
EF43 cells in cotransfection experiments with a reference plas-
mid containing the rabbit b-globin gene under the control of
the simian virus 40 enhancer (4). Correctly initiated mRNA
was detected in nuclease S1 protection experiments with 59-
end-labeled DNA probes. Fragments of 142 nucleotides (nt)
for MMTV and 212 nt for globin were protected from S1
digestion, and the intensity of these bands was measured by
densitometry of the autoradiographs (see Fig. 9).
FIG. 4. DNA methylation interference experiments with end-labeled oligonucleotide DRa (A to C) or DRc (D) and nuclei from liver (L), spleen (S), or L cells (Lc).
The formed complexes were resolved on a nondenaturing acrylamide gel. Oligonucleotides bound to proteins as well as free ones were isolated from the gel and used
for strand cleavage reactions (piperidine, [A and D] or NaOH [B and C]), followed by electrophoresis on a 15% polyacrylamide sequencing gel. The protein-bound
fragments (B) and the free fragments (F) were compared. Relevant residues are indicated. The results of the NaOH treatment were used to analyze the last G
nucleotide at the 39 extremity of the DRa sequence (B and C), as the fragments cleaved at this nucleotide after piperidine treatment were not visible on the gel (A).
FIG. 5. Summary of DNA methylation interference analysis on the coding
strand for the DRa and DRc sequences. Data are from several experiments.
Residues which interfere with protein binding are marked; a high degree of
interference is represented by a thick arrow, and a partial interference is indi-
cated by a thin arrow.
3764 CAVIN AND BUETTI J. VIROL.
The results of several experiments with Ltk2 and EF43 cells
consistently showed that plasmid pLS DRb, which did not
contain any additional MMTV sequences upstream of the dis-
tal glucocorticoid receptor-binding site, had the lowest level of
expression in both cell lines (Fig. 8A and B; Fig. 9A). The
DRa1b construct, which contained the tissue-specific factor-
binding site (DRa) adjacent to the distal glucocorticoid recep-
tor-binding site (DRb), produced only a slight (1.6-fold) in-
crease in transcription compared with DRb alone. The further
addition of the DRc sequence 59 to the DRa element, in
DRc1a1b, produced a 3.7- to 5.1-fold increase in the dexa-
methasone-induced mRNA level in Ltk2 cells and in EF43
cells. In comparison, addition of the remaining 1,000 nucleoti-
des up to the 59 end of the LTR (pLS wild type) showed a
further increase in transcription of only 2-fold (7.2- to 11.4-fold
compared with DRb alone), as a result of the combined effect
of positive and negative regulatory factors which bind in this
region (reviewed in reference 26). Thus, the presence of only
40 bp upstream of the glucocorticoid receptor-binding site is
able to positively modulate the level of transcription from the
MMTV promoter in permissive cell lines.
To better define the roles of the DRa and DRc sites, we
prepared two new plasmids, DRc1b and DRc1c1a1b, for
use in transient transfection assays of Ltk2 cells. With plasmid
DRc1b, we wanted to determine if the presence of the DRc
sequence directly adjacent to the glucocorticoid receptor-bind-
ing site (DRb), without DRa, was sufficient to positively influ-
ence the expression level. We also tested if the addition of a
second DRc sequence in tandem with the first one, in the
construct DRc1c1a1b, could further increase the level of
transcription compared with that found with DRc1a1b, as
many positive regulatory regions were shown to increase their
potency when present in several copies (68). The results
showed that the DRc1b plasmid, lacking the tissue-specific
factor-binding site (DRa), expressed the thymidine kinase
gene at a level which was only slightly higher (1.4-fold) than
that of the reference plasmid with DRb alone (Fig. 8C and 9B).
The construct DRc1c1a1b, containing two DRc sequences,
FIG. 6. Gel retardation assays using nuclear extracts from different tissues and end-labeled oligonucleotides from DRa (top line). (A and B) Oligonucleotide
DRaML (lanes ML) was mutated in three bases (see Fig. 1) shown to be important for binding proteins from nonpermissive tissues (liver and kidney). The formed
complexes were resolved on a nondenaturing polyacrylamide gel. Where indicated, a 250-fold molar excess of competitor DNA (homologous, heterologous, or
nonspecific [VW] oligonucleotide) was included in the preincubation mixture. (C) End-labeled probes were oligonucleotides DRa (odd-numbered lanes) and DRaMS
(even-numbered lanes). DRaMS was mutated on five bases (see Fig. 1) shown to be important for binding factors from permissive tissues. Nuclear extracts used were
from spleen (S), mammary gland (Mgd), B-cell hybridoma (LBB), normal mammary epithelial cells (EF43), fibroblasts (L cell [Lc]), a T-cell lymphoma (RG17), and
mammary tumor cells (GR). The arrows on each side indicate the specific DNA-protein complex.
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gave a 2.4-fold increase in transcription compared with DRb
alone and was therefore less efficient than DRc1a1b, which
showed a 3.7-fold increase in mRNA expression (Fig. 8D and
9B). These data suggest that DRc does not activate transcrip-
tion in an independent manner. In summary, the interaction of
ubiquitous and tissue-specific factors with two binding sites
next to the distal glucocorticoid regulatory element contributes
to a positive regulation of glucocorticoid-stimulated MMTV
transcription in permissive cells.
DISCUSSION
MMTV infection of mice shows a strong tropism for the
mammary glands. However, other tissues such as salivary
glands, lymphoid organs, seminal vesicles, prostate, and testes
are also permissive for the virus. Experiments with transgenic
mice carrying an MMTV LTR linked to a reporter gene
showed a similar tissue specificity of MMTV expression (63,
65, 72), demonstrating that virus entry is not the limiting factor
for gene expression. Some organs, like liver and (in most stud-
ies) kidney, heart, and brain, did not express the transgene
despite the widespread occurrence in these tissues of the glu-
cocorticoid receptor, which is a strong activator of MMTV
transcription, suggesting the existence of further regulatory
factors. Documented mechanisms of modulating hormonal
regulation include interaction of the receptor with factors that
do not bind to the regulatory DNA segment but form specific
and stable protein-protein complexes (82) or, more often, in-
teraction with factors that have their binding sites on the same
DNA. Strong synergistic effects on steroid hormone-induced
transcription have been demonstrated by combination of non-
receptor-binding sites with a receptor-binding site (11, 73).
Recently, it was shown that the juxtaposition of the receptor to
particular factors within a specific complex influences the hor-
mone induced transcription (2). Moreover, differential inter-
action of specific receptor domains with closely adjacent non-
receptor factors may determine distinct hormonal effects (60).
In this report, we have shown that nonreceptor proteins bind-
ing to DNA in the vicinity of the distal glucocorticoid receptor-
binding site modulate the glucocorticoid stimulation of MMTV
transcription.
We analyzed three distinct binding elements in the distal
region of the MMTV promoter corresponding to the glucocor-
ticoid receptor-binding site (DRb) and two sites for nonrecep-
tor proteins (DRa and DRc). A possible interaction among the
proteins binding to these sites is indicated in DNase I protec-
tion experiments by competition of the DRb-binding activity
with the DRc sequence (Fig. 2B, lane 9; Fig. 2C, lane 3) or with
the DRa sequence (Fig. 2B, lane 7) at a high molar excess of
competitor. Moreover, incubation of a liver nuclear extract
with a monoclonal antibody against the purified liver glucocor-
ticoid receptor inhibited the footprint not only on the DRb site
FIG. 7. Gel retardation assay using liver and spleen extracts and end-labeled
DRc or mutated DRcM oligonucleotide. DRcM (see Fig. 1) contains mutations
in two contacted bases shown to be important for binding proteins from liver,
spleen, and L-cell nuclear extracts. The arrow shows the specific DNA-protein
complex formed. Where indicated, a 250-fold molar excess of competitor DNA
(homologous, heterologous, or nonspecific oligonucleotide [DRc, DRcM, or
VW]) was included in the preincubation mixture.
FIG. 8. S1 nuclease protection assay of RNA from transiently transfected
Ltk2 cells (A, C, and D) or EF43 cells (B). Cotransfection experiments were
performed with the different pLS plasmid DNAs (as indicated above each lane)
and a control plasmid, pH514, carrying the rabbit b-globin gene. At least two
different preparations of each pLS plasmid were used in these experiments. The
cultures were treated with dexamethasone for 16 h before RNA extraction. The
arrows indicate the 59-end-labeled protected fragments corresponding to the
MMTV LTR probe (142 nt) (M) and the b-globin probe (212 nt) (G).
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but also on the DRa site (46). Although DRc was not consid-
ered in that study, a close examination of the data showed that
the DRc site was also affected, confirming that the receptor
interacts with both distal binding activities. An interaction be-
tween the glucocorticoid receptor and the DRa- or DRc-bind-
ing activity in solution could lead to a titration of the receptor
with either competitor DNA.
Further evidence for the interaction of the three binding
activities came from transient transfection experiments with
various constructs, showing cooperation of DRa, DRb, and
DRc in the positive modulation of MMTV promoter activity in
permissive cells. Using two permissive cell lines (Ltk2 fibro-
blasts and EF43 mammary epithelial cells), we found that
compared with the pLS DRb plasmid containing only the DRb
site, the addition of DRa upstream of DRb did not significantly
change the level of transcription, whereas the further addition
of DRc, in DRc1a1b, increased the level of hormone-induced
transcription by four- to fivefold (Fig. 8 and 9). In our assay,
the basal level was undetectable. However, deletions encom-
passing this area of the LTR have been shown not to affect the
basal level (21, 81). Interestingly, the presence of the DRc
element directly adjacent to the glucocorticoid receptor-bind-
ing site (DRb), in the absence of DRa, was no longer able to
significantly influence the level of transcription. This result
demonstrates that the DRc sequence cannot activate transcrip-
tion on its own but must act in concert with the two other
binding sites identified in the DR. In a plasmid construction
with the C3HMMTV LTR, a 23-bp substitution between2223
and 2200 was shown to reduce the dexamethasone-induced
expression of a reporter gene, particularly in a mammary cell
line, by about 30% (21). We observed that the sequence of this
C3H element was similar to that of DRc of the GR MMTV
(2203 to 2225). Thus, the 23-bp substitution replaced the
DRc-binding site described in this study. Interestingly, the
sequence of the C3H MMTV-K variant differs from the se-
quence of DRc of the GR MMTV only in its 59 end (from
position 2218) (5, 79). The factor(s) binding the DRc se-
quence probably also recognizes the C3H MMTV-K sequence
since the DRc contact points determined by methylation in-
terference assay (Fig. 4D) were located in the conserved 39 end
and a gel retardation assay comparing the two sequences
showed similar migrations of the protein-DNA complexes
(data not shown). Therefore, these results in different MMTV
strains show the importance of DRc (or equivalent) in the
stimulation of MMTV transcription in permissive cells. Fur-
thermore, our data demonstrate the need for cooperation be-
tween DRc and the neighboring distal binding activities (DRb
and DRa). In this context, analysis of the mouse T-cell recep-
tor enhancer provides an interesting model (19). Three DNA-
binding factors, assembled into a highly specific three-dimen-
sional nucleoprotein complex, activated transcription of the
T-cell receptor, and changes in the relative positions or orien-
tations of the protein binding sites led to inactivation of the
complex.
The control of MMTV transcription in permissive tissues
seems to occur at several levels. In mammary glands, maximal
MMTV expression is obtained by hormonal stimulation acting
through the HRE together with transactivation by mammary
cell-activating factors. These determinants of mammary cell-
specific expression have been described at the extreme 59 part
of the U3 region (around position 21000) in several indepen-
dent studies (21, 41, 50, 51, 81), although no agreement has yet
been reached on their precise location. This regulation seems
to be achieved by a concerted action of transcription factors
binding to multiple regulatory sites in this region, including
MAF (mammary cell-activating factor) and a member of the
CTF/NF-1 family (49), MP4 (41), a putative factor binding to
a mammary gland enhancer (51), and factors described accord-
ing to their DNA recognition sites (49, 81). Using transgenic
mice carrying an MMTV LTR deleted of all 59 LTR sequences
upstream of 2364, Mok et al. (51) showed an increase of
transgene expression in lactating females comparable to that
seen in mice carrying the complete LTR. These authors con-
cluded that the major determinant of the strong increase of
viral expression that occurs during lactation must include the
glucocorticoid response elements. Our results are interesting
in this context, as they point to elements that are capable of
modulating the hormonal response. We have demonstrated
that cooperation of the glucocorticoid receptor with two other
distinct binding activities in the DR, in the absence of the 59
end of the LTR, is sufficient to significantly increase the level
of MMTV transcription in permissive cells. Moreover, a lower
but significant level of expression occurs in other permissive
tissues such as salivary glands, spleen, and lymphocytes in
which regulatory factors different from the mammary cell-ac-
tivating ones may play an important role. In our studies of the
DR, the tissue specificity of factors binding to DRa was sug-
gested by the presence of hypersensitive sites in the footprints
FIG. 9. Quantitation of MMTV-specific transcription in transiently trans-
fected L cells (shaded bars) or mammary epithelial EF43 cells (open bars). The
results of several S1 mapping experiments similar to the one shown in Fig. 8 were
analyzed by scanning densitometry of autoradiographs, and the data were nor-
malized to those for the b-globin internal standard. They are expressed in fold
induction (6 standard deviation) compared with the signal found with DRb. The
number (n) of transfections performed with each construct was as follows: in L
cells, n 5 5 with the exception of DRcb and DRccab, for which n 5 3; in EF43
cells, n 5 3. wt, wild type.
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observed only with nuclear extracts from nonpermissive tissues
(liver [Fig. 2] and kidney [data not shown]). Gel retardation
assays with wild-type (DRa) and mutated (DRaML) oligonu-
cleotides (Fig. 3A, 6A, and 6B) and methylation interference
assays (Fig. 5) demonstrated that the major DRa-binding ac-
tivities are indeed distinct and specific to permissive (mamma-
ry gland and mammary epithelial cell lines EF43 and GR) or
nonpermissive (liver and kidney) tissues and cell lines. A very
low concentration of the permissive-type DRa factor was ob-
served occasionally in nonpermissive tissue extracts; however,
this did not influence the pattern of DNase I footprints ob-
served with these extracts. We showed by gel retardation assays
with a mutated DRaMS oligonucleotide that the DRa-binding
activity is the same in permissive tissues of different origin
(e.g., mammary and lymphoid [Fig. 6C]), in contrast to the
mammary cell-activating factors mentioned above (MAF and
MP4), which were expressed mainly in cells of mammary ori-
gin.
MMTV is known to be expressed in lymphoid cells (42), and
infected lymphocytes were shown to harbor persistent virus
(30, 78). Moreover, they play an essential role in the infectious
process, as an MMTV-encoded product (superantigen) ex-
pressed in B cells directly influences the host immune system
(1, 14). The molecular mechanisms controlling MMTV expres-
sion in lymphocytes are, however, not well understood. King
and Corley (36) showed that the level of MMTV transcription
can be increased by treatment of B cells with various sub-
stances such as lipopolysaccharide or lymphokines via a path-
way that is different from the one used by dexamethasone. As
our results suggest that the factors binding DRa are similar in
nuclear extracts from the mammary gland and various lym-
phoid tissues or cell lines, and as a particularly strong binding
activity for the DRc sequence was observed in spleen extracts,
it is possible that these regions positively influence the hor-
mone-regulated pathway in lymphoid tissues. Thus, we plan to
test the expression in B-cell lines of our plasmids carrying
different parts of the DR.
In the absence of a sufficiently differentiated transfectable
liver cell line which could prevent MMTV transcription, it is
not yet possible to test our hypothesis that the protein(s) bind-
ing to the DRa site may repress glucocorticoid-induced tran-
scription in nonpermissive cells, for example by competing with
a positive regulatory DRa-binding factor. Alternatively, repres-
sion may occur by direct interaction between the DRa-binding
factor and the receptor or by steric hindrance of contacts
between the receptor and the transcription initiation complex
(53, 61). The strong signal observed in gel retardation assays
with liver and kidney nuclear extracts suggests that the DRa-
binding activity is abundant in these tissues or binds with a high
affinity to the DRa site (Fig. 2A and 6B). Complexes with
similar mobility were not observed with extracts from several
transfectable hepatoma cell lines (mouse FMH-202 [58], rat
FTO-2B [35], and human HepG2 [data not shown]), suggesting
that these cell lines lack the DRa-binding protein found in
liver. The expression of one hepatocyte factor may be depen-
dent on another, as shown recently in the case of a dediffer-
entiated hepatoma cell line in which the absence of hepatic
nuclear factor 4 (HNF-4) also abolished the expression of
HNF-1a (38). The recent identification of these and other
liver-enriched transcription factors and of the genes encoding
them (which can be introduced into cultured cells) (34, 71) will
allow us to test the expression of a negative-acting factor or
may reveal novel regulatory interactions.
The sequence TTTAAATAA of DRa fits relatively well with
the reported consensus binding site for the transcription factor
C/EBP (MTTRCNNMA, where M is C or A, N is A, C, G, or
T, and R is G or A) (66). Furthermore, our sequence shows a
high degree of homology (8 of 9 bp) with a low-affinity binding
site for C/EBP in the C region of the chicken vitellogenin II
promoter, which is active in hepatocytes (70). In a gel retar-
dation assay with a DRa probe, an oligonucleotide containing
the CAAT motif of the herpes simplex virus thymidine kinase
gene that also binds the factor C/EBP (23) efficiently competed
for the complex formed with spleen nuclear extract but not the
major liver complex (data not shown). Interestingly, recently
described members of the C/EBP family are not restricted to
the liver but are expressed in many different tissues and cell
lines (64). Therefore, we are pursuing the idea that the DRa
factor found mainly in permissive tissues (spleen) may be a
member of this family. HNF-3 binds an 11-bp motif located in
the upstream sequence of the tyrosine aminotransferase
(TAT) gene that shows only 6-bp homology with the HNF-3
consensus binding sequence (55). Interestingly, we observed a
sequence in DRa which has six base identities with this TAT-
2.5 HNF-3 binding site. A functional cooperation between a
distantly located glucocorticoid regulatory element and an
HNF-3-binding site results in activation of TAT gene tran-
scription (55). On the other hand, HNF-3 has also been shown
to act as an inhibitor of transcription (24). We are currently
investigating if the DRa factor in nonpermissive tissues (liver)
is a member of the HNF-3 family (15). A search of various data
banks of transcription factor-binding sites did not reveal any
other significant homologies with the DRa or DRc site.
In conclusion, we have established that in permissive cells,
the combination of a tissue-specific factor(s) and a ubiquitous
factor(s) positively modulates the transcriptional stimulation
elicited by the glucocorticoid receptor. This positive effect can
be interpreted as a facilitation or stabilization of the interac-
tion between the receptor and its binding site and/or at the
level of activation of the transcriptional machinery by interac-
tion with targets within the basal transcription complex (75).
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